Mouse Anti-Cytokeratin 8-HRP

Cat. No.
10080-05  
Size
1.0 mL  
Price (USD)
$300.00 
Clone SB37b
Isotype Mouse (BALB/c) IgG2aκ
Isotype Control Mouse IgG2a-HRP
Immunogen Recombinant C-terminal cytokeratin 8
Specificity Cytokeratin 8
Alternalte Name(s) CK 8, keratin 8
Description Keratins are a family of intermediate filament proteins that assemble into filaments through forming heterodimers of one type I keratin (keratins 9 to 23) and one type II keratin (keratins 1-8). The two keratin types share only 30% sequence homology. Keratins demonstrate tissue- and differentiation-specific expression profiles. Cytokeratin 8 belongs to the type B (basic) subfamily of keratins and exists in combination with keratin 18. It is expressed in all simple type epithelia tissues (e.g., liver, pancreas, kidney, gut epithelial lining) but not in stratified squamous epithelia. Cytokeratin 8 is also present in the majority of adenocarcinomas and ductal carcinomas but is absent in most squamous cell carcinomas.
Format/Conjugate HRP (Horseradish Peroxidase)
Buffer Formulation Supplied in a stock solution of 50% glycerol/50% PBS, pH 7.4; No preservative added
Volume 1.0 mL
Storage & Handling Store at 2-8°C
Please refer to product specific SDS
Applications
Applications for relevant formats of this clone include -
Immunocytochemistry – Quality tested 1
ELISA – Quality tested
Immunohistochemistry-Paraffin Sections – Reported in literature 2
Flow Cytometry 3
Western Blot 3
Immunoprecipitation 3
Recommended Dilutions Please refer to product specific Technical Bulletin
  • Paraffin embedded human gastric cancer tissue was stained with Mouse IgG2a-HRP isotype control (SB Cat. No. 0103-05; left) and Mouse Anti-Cytokeratin 8-HRP (SB Cat. No. 10080-05; right) followed by DAB and hematoxylin.

Paraffin embedded human gastric cancer tissue was stained with Mouse IgG2a-HRP isotype control (SB Cat. No. 0103-05; left) and Mouse Anti-Cytokeratin 8-HRP (SB Cat. No. 10080-05; right) followed by DAB and hematoxylin.
 
References
1. Chatin B, Mével M, Devallière J, Dallet L, Haudebourg T, Peuziat P, et al. Liposome-based formulation for intracellular delivery of functional proteins. Mol Ther Nucleic Acids. 2015;4:e244. (ICC)
2. Wang D. Individualized cardiovascular medicine: identifying new mechanisms to inhibit the development of myointimal hyperplasia [dissertation]. Hamburg (Germany): University Medical Center Hamburg-Eppendorf; 2015. (IHC-PS)
3. SouthernBiotech unpublished data (FC, WB, IP)